Datapoint: Novo Scores Cardiovascular Expansion for Wegovy

March 14

The FDA signed off on a key label expansion for Novo Nordisk’s much-discussed weight loss drug Wegovy (semaglutide). The glucagon-like peptide-1 (GLP-1) receptor agonist is now approved to reduce the risk of cardiovascular death, heart attack and stroke in obese or overweight adult patients with cardiovascular disease. Trial data shows Wegovy reduced the risk of major adverse cardiovascular events by 20% compared to a placebo. For the treatment of obesity, Wegovy currently holds covered or better status for 53% of all insured lives. Just 11% have preferred access without any utilization management restrictions, while 45% have no covered access to the drug.

SOURCE: MMIT Analytics, as of 3/13/24